SCHEMBL6296596

SCHEMBL6296596

CC1=C(C(=O)NN)C(c2ccccc2Cl)c2c[nH]nc2N1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.41
KDM4E B2RXH2 5/20 0.41
HSD17B10 Q99714 5/20 0.41
GAA P10253 4/20 0.41
HPGD P15428 4/20 0.41
TSHR P16473 4/20 0.41
GLA P06280 3/20 0.41
CASP1 P29466 3/20 0.41
CASP7 P55210 3/20 0.41
POLB P06746 1/20 0.41
TBXA2R P21731 3/20 0.40
ADRA1A P35348 3/20 0.40
SLC6A3 Q01959 3/20 0.40
HTR1A P08908 2/20 0.40
ADRA2A P08913 2/20 0.40
CHRM1 P11229 2/20 0.40
DRD1 P21728 2/20 0.40
SLC6A2 P23975 2/20 0.40
OPRM1 P35372 2/20 0.40
DRD3 P35462 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6293653 0.87 KDM4E (0.51) ALDH1A1KDM4EHSD17B10GAAHPGD
SCHEMBL7017903 0.87 ALDH1A1 (0.41) ALDH1A1KDM4EHSD17B10GAAHPGD
SCHEMBL6296464 0.85 TSHR (0.56) ALDH1A1KDM4EHSD17B10GAAHPGD
SCHEMBL6292177 0.84 ALDH1A1 (0.39) ALDH1A1KDM4EHSD17B10GAAHPGD
SCHEMBL6296978 0.82 NR3C2 (0.45) ALDH1A1KDM4EHSD17B10GAAHPGD
SCHEMBL6292201 0.81 HTR1A (0.46) TSHRPOLBTBXA2RADRA1ASLC6A3
SCHEMBL6293581 0.76 TBXA2R (0.49) ALDH1A1KDM4EHSD17B10GAAHPGD
SCHEMBL6297478 0.76 ABCB11 (0.52) ALDH1A1KDM4EHSD17B10GAAHPGD
SCHEMBL6296656 0.76 TBXA2R (0.46) ALDH1A1KDM4EHSD17B10GAAHPGD
SCHEMBL7441431 0.75 PYGL (0.39) ALDH1A1KDM4EHSD17B10GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6977262-B2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2005-12-20 US disclosed
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-03-18 US disclosed
EP-1355909-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-10-29 EP disclosed
WO-2002062795-A9 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2002-10-10 WO disclosed
WO-2002062795-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof GSK3B, GSK3A, PYGB ALDH1A1 944/4885KDM4E 1992/4885HSD17B10 1715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.